Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Gastroduodenal neuroendocrine neoplasms including gastrinoma - Update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) (2022) Rydzewska G, Strzelczyk J, Bednarczuk T, Bolanowski M, Borowska M, Chmielik E, Cwikla JB, et al. Journal article Motorized spiral enteroscopy: Results of an international multicenter prospective observational clinical study in patients with normal and altered gastrointestinal anatomy (2022) Beyna T, Moreels T, Arvanitakis M, Pioche M, Saurin JC, May A, Knabe M, et al. Journal article Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome (2022) Koumarianou A, Daskalakis K, Tsoli M, Kaltsas G, Pavel ME Journal article, Review article Transcriptomes of MPO-Deficient Patients with Generalized Pustular Psoriasis Reveals Expansion of CD4+ Cytotoxic T Cells and an Involvement of the Complement System (2022) Haskamp S, Frey B, Becker I, Schulz-Kuhnt A, Atreya I, Berking C, Pauli D, et al. Journal article Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres (2022) Zandee WT, Merola E, Poczkaj K, de Mestier L, Klümpen HJ, Geboes K, de Herder WW, Munir A Journal article Pig models for Duchenne muscular dystrophy – from disease mechanisms to validation of new diagnostic and therapeutic concepts (2022) Stirm M, Fonteyne LM, Shashikadze B, Stöckl JB, Kurome M, Keßler B, Zakhartchenko V, et al. Journal article, Review article The first virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic remission in Ulcerative Colitis (2022) Iacucci M, Cannatelli R, Parigi TL, Buda A, Labarile N, Nardone OM, Tontini GE, et al. Conference contribution A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative Colitis (2022) Villanacci V, Parigi TL, Del Amor R, Esbri PM, Gui X, Bazarova A, Bhandari P, et al. Conference contribution A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis (2022) Peyrin-Biroulet L, Arkkila P, Armuzzi A, Atreya R, Danese S, Ferrante M, Guardiola J, et al. Conference contribution Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies (2022) Atreya R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, et al. Conference contribution